COMPASS Pathways plc (CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is listed on the NASDAQ exchange under the ticker symbol "CMPS".
Founded in 2016 and located in London, UK, COMPASS Pathways is at the forefront of medical and scientific research with a vision to create a world of mental wellbeing. They are pioneering the development of a new model of mental health care to transform lives and also the health care system. The company aims to enhance and deliver better treatments that will make a significant difference for patients and their families affected by mental health complications.
COMPASS Pathways has made a remarkable leap into a new kind of therapy by researching and developing psilocybin therapy, a form of psychedelic treatment. Psilocybin is a naturally occurring psychedelic compound found in certain types of mushrooms. They are studying this new approach to therapy by developing what could be the first regulatory-approved, prescription treatment for patients with treatment-resistant depression.
In 2019, COMPASS received Breakthrough Therapy designation from the FDA for its psilocybin therapy for treatment-resistant depression. This status will help to accelerate the development and review process and is only granted to drugs that show significant treatment advantages over existing options.
The therapy developed by COMPASS, known as COMP360, is a synthesized psilocybin, precisely dosed and combined with psychological support from a specially trained therapist. The therapy is used in controlled settings to help provide a safe and potentially transformative patient experience.
Through harnessing the therapeutic potential of psilocybin, COMPASS Pathways represents an innovative approach to psychiatric treatment. This could make significant strides in the treatment of major depressive disorder, a condition affecting millions worldwide, revolutionising patient care and potentially shaking up mental healthcare for good.
They are committed to conducting high-quality, rigorously controlled clinical trials to provide evidence to medical, regulatory and ethical review boards, paving the way for future mental health treatments.
As a company, COMPASS Pathways continues to make significant strides within their field, symbolising a hope for future developments in mental health care and posing the potential for novel strategies in care and treatment.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Compass Pathways has launched "Change the Tune in TRD," a new U.S. healthcare provider education initiative. This campaign aims to deepen understanding and increase recognition of treatment-resistant depression (TRD) by exploring its neurobiology and care pathways. The initiative will debut at Psych Congress 2026, offering resources and insights to support earlier identification and more informed conversations about TRD.
Compass Pathways has announced the recipients of its U.S. grant program aimed at developing post-approval COMP360 provider training. Five organizations were selected to create training programs for healthcare providers to ensure high-quality treatment experiences for patients receiving COMP360, if approved. This initiative underscores Compass Pathways' commitment to scientific rigor, patient safety, and preparing the healthcare workforce for future mental health care innovations.
Compass Pathways' stock rose over 11% after the company released positive 52-week data from its Phase 3 COMP005 study for COMP360, a psilocybin treatment for treatment-resistant depression. The data showed durable and long-lasting mental health benefits, with supplemental dosing deepening responses and extending efficacy up to one year. The company is currently undergoing an FDA New Drug Application submission and aims for a commercial launch in the first half of 2027.